Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock Holdings Lowered by M&T Bank Corp

M&T Bank Corp reduced its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 70.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,128 shares of the biopharmaceutical company's stock after selling 79,979 shares during the period. M&T Bank Corp's holdings in Halozyme Therapeutics were worth $2,178,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Bessemer Group Inc. grew its holdings in Halozyme Therapeutics by 62.9% during the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock worth $34,000 after acquiring an additional 207 shares in the last quarter. D. E. Shaw & Co. Inc. boosted its holdings in shares of Halozyme Therapeutics by 171.2% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company's stock valued at $39,750,000 after buying an additional 524,802 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Halozyme Therapeutics by 199.0% in the 1st quarter. GAMMA Investing LLC now owns 2,802 shares of the biopharmaceutical company's stock valued at $179,000 after buying an additional 1,865 shares during the period. Fifth Third Bancorp boosted its holdings in shares of Halozyme Therapeutics by 29.4% in the 1st quarter. Fifth Third Bancorp now owns 10,017 shares of the biopharmaceutical company's stock valued at $639,000 after buying an additional 2,276 shares during the period. Finally, Farther Finance Advisors LLC boosted its holdings in shares of Halozyme Therapeutics by 620.5% in the 1st quarter. Farther Finance Advisors LLC now owns 5,505 shares of the biopharmaceutical company's stock valued at $341,000 after buying an additional 4,741 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock traded down $0.48 during midday trading on Friday, reaching $57.15. 1,242,806 shares of the stock traded hands, compared to its average volume of 1,756,733. The company has a current ratio of 8.39, a quick ratio of 7.30 and a debt-to-equity ratio of 3.13. The firm has a fifty day moving average price of $55.03 and a two-hundred day moving average price of $56.88. The firm has a market cap of $7.04 billion, a price-to-earnings ratio of 15.20, a PEG ratio of 0.38 and a beta of 1.15. Halozyme Therapeutics, Inc. has a fifty-two week low of $42.01 and a fifty-two week high of $70.51.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 EPS for the quarter, topping analysts' consensus estimates of $0.98 by $0.13. Halozyme Therapeutics had a net margin of 44.76% and a return on equity of 136.91%. The company had revenue of $264.86 million for the quarter, compared to the consensus estimate of $231.21 million. During the same period in the previous year, the firm earned $0.79 EPS. Halozyme Therapeutics's revenue was up 35.2% on a year-over-year basis. On average, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 4,497 shares of the business's stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $60.37, for a total transaction of $271,483.89. Following the sale, the director directly owned 28,611 shares in the company, valued at approximately $1,727,246.07. The trade was a 13.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Helen Torley sold 20,000 shares of the business's stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $56.43, for a total transaction of $1,128,600.00. Following the sale, the chief executive officer owned 733,719 shares in the company, valued at $41,403,763.17. This trade represents a 2.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 64,497 shares of company stock worth $3,533,884 over the last 90 days. 2.40% of the stock is owned by insiders.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Morgan Stanley lowered shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and decreased their price target for the company from $73.00 to $62.00 in a report on Wednesday, May 14th. Leerink Partnrs lowered shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday, May 13th. Leerink Partners lowered shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price target for the company. in a report on Tuesday, May 13th. Wells Fargo & Company lifted their price target on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a report on Wednesday, May 7th. Finally, The Goldman Sachs Group began coverage on shares of Halozyme Therapeutics in a report on Thursday. They issued a "neutral" rating and a $55.00 price target for the company. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $62.50.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.